126 related articles for article (PubMed ID: 38084857)
21. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
22. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
23. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan.
Wang JH; Chen CH; Chang CM; Feng WC; Lee CY; Lu SN
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):504-508. PubMed ID: 31350109
[TBL] [Abstract][Full Text] [Related]
25. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
[TBL] [Abstract][Full Text] [Related]
26. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
[TBL] [Abstract][Full Text] [Related]
27. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.
Shiha G; Metwally AM; Soliman R; Elbasiony M; Mikhail NNH; Easterbrook P
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):778-789. PubMed ID: 30030068
[TBL] [Abstract][Full Text] [Related]
28. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan.
Tsai MC; Kee KM; Chen YD; Lin LC; Tsai LS; Chen HH; Lu SN
J Gastroenterol Hepatol; 2007 Jan; 22(1):92-8. PubMed ID: 17201888
[TBL] [Abstract][Full Text] [Related]
29. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.
Tai CM; Yu ML
Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851
[TBL] [Abstract][Full Text] [Related]
31. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.
Lee YC; Wang JL; Dong YH; Chen HC; Wu LC; Chang CH
PLoS Med; 2019 Sep; 16(9):e1002894. PubMed ID: 31518344
[TBL] [Abstract][Full Text] [Related]
32. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
[TBL] [Abstract][Full Text] [Related]
33. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2021 Feb; 74(2):303-311. PubMed ID: 32931878
[TBL] [Abstract][Full Text] [Related]
34. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
35. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan.
Tsai PC; Dai CY; Huang CI; Yeh ML; Huang CF; Hsieh MH; Yang JF; Hsu PY; Liang PC; Lin YH; Jang TY; Hsieh MY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL; Chang WY
Kaohsiung J Med Sci; 2022 Jul; 38(7):694-702. PubMed ID: 35485737
[TBL] [Abstract][Full Text] [Related]
36. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
Hsu YC; Lin JT; Ho HJ; Kao YH; Huang YT; Hsiao NW; Wu MS; Liu YY; Wu CY
Hepatology; 2014 Apr; 59(4):1293-302. PubMed ID: 24122848
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus infection in Australian psychiatric inpatients: A multicenter study of seroprevalence, risk factors and treatment experience.
Ramachandran J; Budd S; Slattery H; Muller K; Mohan T; Cowain T; Tilley E; Baas A; Wigg L; Alexander J; Woodman R; Kaambwa B; Wigg A
J Viral Hepat; 2019 May; 26(5):609-612. PubMed ID: 30576038
[TBL] [Abstract][Full Text] [Related]
38. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
[TBL] [Abstract][Full Text] [Related]
40. Systematic overview of hepatitis C infection in the Middle East and North Africa.
Chaabna K; Cheema S; Abraham A; Alrouh H; Lowenfels AB; Maisonneuve P; Mamtani R
World J Gastroenterol; 2018 Jul; 24(27):3038-3054. PubMed ID: 30038471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
